Results 231 to 240 of about 65,300 (300)

Effectiveness of Amenamevir Vs. Valacyclovir in Preventing Herpes Zoster‐Related Hospitalization and Complications: A Target Trial Emulation Using a Large Japanese Claims Database

The Journal of Dermatology, EarlyView.
ABSTRACT Amenamevir is a novel anti‐herpes zoster drug that is increasingly used in Japan because of its once‐daily administration and lack of renal dose adjustment requirements. However, evidence of its clinical effectiveness is limited. This study aimed to estimate the clinical effectiveness of amenamevir vs. valacyclovir in preventing zoster‐related
Yasuhiro Kano, Yuya Kimura, Hideo Yasunaga   +2 more
wiley   +1 more source

Recent progress in cGAS-STING agonist design and mechanisms of cancer immune modulation. [PDF]

RSC Chem Biol
Wang L, Nafees M, Fei H, Hanif M, Yang P.   +4 more
europepmc   +1 more source

Randomized, single‐centre, double‐blinded repeated dose investigation of safety and tolerability of ocular administrations of a novel silica eye drop product in healthy volunteers

Acta Ophthalmologica, EarlyView.
Abstract Purpose Managing ocular diseases often requires frequent eye drop administration, which can challenge patient compliance. A long‐acting eye drop technology using an amorphous synthetic silica composite was developed to address this. Our study aimed to assess the safety and tolerability of the Silica Eye Drop platform in healthy volunteers over
Aleksandra Poluianova, Marceline N. Akieh‐Pirkanniemi, Arto Hartikainen, Hanna Arstila, Kai Kaarniranta, Lasse Leino   +5 more
wiley   +1 more source

Engineering a Glucose-Responsive Glucagon Prodrug Through Arginine-Phenylboronic Acid Pendant Modification. [PDF]

Small Sci
DeWolf EL, Chen W, Webber B, Power EM, Kilmer R, Kadu P, Xian S, Webber MJ.   +7 more
europepmc   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

An AKR1C3-activated kinase inhibitor prodrug. [PDF]

RSC Chem Biol
Li Z, Martinez M, Byun WS, Thathireddy A, Qiu T, Wang Y, Katzengruber L, Chouldjian A, Lu W, Ji W, Che J, Zhang T, Hinshaw SM, Gray NS.   +13 more
europepmc   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Lipo-Glc-1,6-P₂: A Bioprecursor Prodrug for Phosphomannomutase-2 Congenital Disorder of Glycosylation. [PDF]

IUBMB Life
Sodano F, Monticelli M, Hay Mele B, Rolando B, Lazzarato L, De Simone A, Andrisano V, Paris D, Rimoli MG, Cubellis MV, Andreotti G.   +10 more
europepmc   +1 more source

Diltiazem N‐oxide, a novel ischaemia‐activated prodrug, prevents ischaemia‐induced ventricular fibrillation without off‐target adverse effects

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Ventricular fibrillation (VF) in coronary heart disease accounts for up to 70% of sudden cardiac death. We examined whether diltiazem N‐oxide (DNO) has ischaemia‐selective antiarrhythmic activity. Experimental Approach Randomised and blinded experiments were performed in rat isolated hearts and in anaesthetised rats to ...
Louise M. Hesketh, Gabriel A. Watson, Francesca Mazzacuva, Zoe Hoare, Thomas R. Eykyn, Michael J. Curtis   +5 more
wiley   +1 more source

Heterocyclic modified paclitaxel prodrug nanoassemblies for stimuli-responsive delivery <i>via</i> lysosomal escape. [PDF]

Acta Pharm Sin B
Han M, Xu H, Yuan J, Li W, Zhang H, Fang H, Kuang Z, Yu Y, Wang D, Zhao Z, Luo C, Sun B, Sun J.   +12 more
europepmc   +1 more source